The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Is elimination of HCV in 2030 realistic in Central Europe
Robert Flisiak1, Dorota Zarebska-Michaluk2, Sona Frankova3, Ivica Grgurevic4, Bela Hunyady5, Peter Jarcuska6, Limas Kupcinskas7, MichaelMakara8, Marieta Simonova9, Jan Sperl3, Ieva Tolmane10, Adriana Vince11
Author information
Affiliations collapse1Department of Infectious Diseases and Hepatology, Medical University of Bialystok, Bialystok, Poland.
2Department of Infectious Diseases, Jan Kochanowski University, Kielce, Poland.
3Department of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
4Department of Gastroenterology, Hepatology and Clinical Nutrition, University Hospital Dubrava, University of Zagreb School of Medicine, Zagreb, Croatia.
5Department of Gastroenterology, First Department of Medicine, Somogy County Kaposi Mór Teaching Hospital, Kaposvár and University of Pécs, Clinical Center, Pécs, Hungary.
62nd Department of Internal Medicine, Louis Pasteur University Hospital and Pavol Jozej Šafárik University, Faculty of Medicine, Kosice, Slovakia.
7Institute for Digestive Research and Department of Gastroenterology, Lithuanian University of Health Sciences, Kaunas, Lithuania.
8Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary.
9Department of Gastroenterology, HPB Surgery and Transplantology, Military Medical Academy, Sofia, Bulgaria.
10Latvian Center of Infectious Diseases, Riga East University Hospital, Hepatology Department, Faculty of Medicine, University of Latvia, Riga, Latvia.
11Department for Viral Hepatitis, University Hospital of Infectious Diseases, University of Zagreb School of Medicine, Zagreb, Croatia.
Abstract
According to the recent data presented by Central-European HCV experts, the estimated prevalence of HCV is between 0.2% and 1.7% in certain countries in this region. There are no financial limitations to access to treatment in most countries. Patients in these countries have access to at least one pangenotypic regimen. The most common barriers to the elimination of HCV in Central Europe are a lack of established national screening programmes and limited political commitment to the elimination of HCV. Covid-19 has significantly affected the number of patients who have been diagnosed and treated, thus, delaying the potential elimination of HCV. These data suggest that the elimination of HCV elimination projected by WHO before 2030 will not be possible in the Central Europe.